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Regulated Proenkephalin Expression in Human Skin
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Alexander Pisarchik4, Andre Szczesniewski5 and Desmond J. Tobin6
Skin responds to environmental stressors via coordinated actions of the local neuroimmunoendocrine system.
Although some of these responses involve opioid receptors, little is known about cutaneous proenkephalin
expression, its environmental regulation, and alterations in pathology. The objective of this study was to assess
regulated expression of proenkephalin in normal and pathological skin and in isolated melanocytes, keratinocytes,
fibroblasts, and melanoma cells. The proenkephalin gene and protein were expressed in skin and cultured cells,
with significant expression in fibroblasts and keratinocytes. Mass spectroscopy confirmed Leu- and
Met-enkephalin in skin. UVR, Toll-like receptor (TLR)4, and TLR2 agonists stimulated proenkephalin gene
expression in melanocytes and keratinocytes in a time- and dose-dependent manner. In situ Met/Leu-enkephalin
peptides were expressed in differentiating keratinocytes of the epidermis in the outer root sheath of the hair
follicle, in myoepithelial cells of the eccrine gland, and in the basement membrane/basal lamina separating
epithelial and mesenchymal components. Met/Leu-enkephalin expression was altered in pathological skin,
increasing in psoriasis and decreasing in melanocytic tumors. Not only does human skin express proenkephalin,
but this expression is upregulated by stressful stimuli and can be altered by pathological conditions.
Journal of Investigative Dermatology (2011) 131, 613–622; doi:10.1038/jid.2010.376; published online 30 December 2010
INTRODUCTION
The skin is the largest body organ and is continuously
exposed to environmental stress, including solar radiation;
physical, chemical, and biological insults; and antigenic
stimuli (Slominski and Wortsman, 2000; Slominski et al.,
2000c, 2008b; Tobin, 2006). To protect local and global
homeostasis, the skin responds to these insults through
complex biological, biochemical, and chemical activities
that are coordinated by the local neuroendocrine and
immune systems (Slominski and Wortsman, 2000; Slominski
et al., 2000c, 2004, 2008b; Arck et al., 2006; Elias, 2007). An
example of this local activity is the local production of
proopiomelanocortin-derived peptides (Slominski et al.,
2000c), corticotropin-releasing factor and urocortins
(Slominski et al., 2000a, b), acetylcholine (Grando and
Horton, 1997), catecholamines (Schallreuter et al., 1995),
serotonin (Slominski et al., 2005), and melatonin (Slominski
et al., 2008a). These neurohormones, neurotransmitters, and
neuropeptides regulate the local homeostasis through inter-
action with corresponding receptors expressed on skin cells
or nerve endings, allowing local neural regulation or
transmission to the brain (Slominski and Wortsman, 2000).
The enkephalins belong to one of three well-characterized
families of endogenous opioid peptides produced by the
body, with the Met-enkephalin peptide sequence coded for
by both the enkephalin gene and the proopiomelanocortin
gene, while the Leu-enkephalin peptide sequence is coded
for by both the enkephalin gene and the dynorphin gene.
The receptors for enkephalin include m-, k-, and d-opioid
receptors, which are expressed on skin cells and on sensory
nerve endings in the skin, and their activation can regulate
keratinocyte and melanocyte activities (Zagon et al., 1996;
Nissen and Kragballe, 1997; Bigliardi et al., 1998, 2003;
Bigliardi-Qi et al., 1999). Proopiomelanocortin-derived b-
endorphin, one of their endogenous ligands (Bigliardi-Qi
et al., 2000, 2004; Kauser et al., 2003, 2004; Tobin, 2006), is
locally produced in the skin (Slominski et al., 1992, 1993;
Furkert et al., 1997; Slominski, 1998) and stimulates
epidermal and follicular melanogenesis (Kauser et al., 2003,
2004). Although there are reports demonstrating the presence
of Met-enkephalin antigen in adult mammalian skin (Weihe
et al., 1983; Chew and Leung, 1991; Zagon et al., 1996;
Nissen et al., 1999), there is a shortage of information on
local proenkephalin gene expression and its relationship to
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skin pathology and the environmental regulation of proenke-
phalin (PENK) expression.
PENK is a large protein precursor that is highly conserved
from Xenopus to humans (Comb et al., 1983; Martens and
Herbert, 1984; Felig and Frohman, 2001). It is processed through
the action of PC1 and PC2 convertases to produce several copies
of Met-enkephalin and Leu-enkephalin in a 4:1 ratio, as well as
the opioids hepta- and octapeptide (Met-enkephalin–Arg–Phe
and Met-enkephalin–Arg–Gly–Leu, respectively) and C- or N-
terminally extended variants of these peptides (Goumon et al.,
2000; Kieffer et al., 2003; Peinado et al., 2003; Ozawa et al.,
2007). PENK-derived peptides exhibit opiate-like activity; act as
neurotransmitters, neuromodulators, and neurohormones; and
are involved in analgesia, responses to stress and pain, and
regulation of appetite and sleep (Felig and Frohman, 2001; Le
Merrer et al., 2009). In addition to its role in the central and
peripheral nervous system, the PENK gene is expressed in
several nonneuronal tissues, including endocrine glands such as
the adrenal medulla, cells of the immune system, and embryonal
skin mesenchymal cells (Blalock, 1989; Kew and Kilpatrick,
1990; Polakiewicz and Rosen, 1990; Behar et al., 1991, 1994;
Kuis et al., 1991; Polakiewicz et al., 1992; Rosen et al., 1995).
Thus, depending on the site of production or target cells, the
PENK-derived peptides can act in a para- or autocrine manner
affecting immune activities, having direct antimicrobial activ-
ities, regulating cell proliferation and differentiation, and playing
a role in brain development (Nissen and Kragballe, 1997;
Goumon et al., 1998; Kamphuis et al., 1998; Metz-Boutigue
et al., 2000; Tasiemski et al., 2000a; Kieffer et al., 2003).
To address some significant gaps in our current knowledge
and to further define elements of the local neuroimmuno-
endocrine system, we have carefully investigated the expres-
sion of PENK gene and protein with corresponding Met- and
Leu-enkephalin peptides in human skin under physiological
and pathological conditions and in cultured normal and
malignant keratinocytes, melanocytes, and fibroblasts, using
a range of molecular, analytical, cell biology, and in situ
techniques. To clarify the regulatory mechanisms of PENK
expression, we tested the effects of UVB, the Toll-like
receptor 4 (TLR4) agonist lipopolysaccharide, and the TLR2
agonist PAM3CSK4 on PENK expression in epidermal
melanocytes and keratinocytes.
RESULTS
PENK gene and protein are expressed in the human skin and
skin cells
RT-PCR amplification (30 cycles) of complementary mRNA
from skin biopsy specimens and cultured normal and
immortalized epidermal keratinocytes, melanocytes, and
dermal fibroblasts and six melanoma lines derived from
melanomas at radial, vertical, and metastatic growth phases
all demonstrated a 204-kb transcript with 100% homology
with the corresponding PENK gene fragment (Figure 1a).
Western blot and immunofluorescence studies demonstrated
that this PENK messenger RNA (mRNA) expression is
associated with production of the corresponding protein
(Figure 1b and c). Figure 1b and Supplementary Figure S1
online demonstrate the presence of a PENK protein precursor
with a molecular weight slightly above 30 kDa in human
normal epidermal and fibroblasts (Figure 1b, left panel); it
was absent in membranes incubated with nonimmune serum
(Figure 1b, right panel). The band of the same size was seen
in AtT-20 pituitary cells transfected with PENK plasmid (not
shown). Supplementary Figure S1 online again demonstrates
the presence of PENK with a molecular weight slightly above
30 kDa in human normal epidermal keratinocytes and
melanocytes, HaCaT keratinocytes, dermal fibroblasts, and
melanoma cells, as well as additional double bands of higher
molecular weight (440 kDa) in fibroblasts and normal and
immortalized keratinocytes, which may represent post-
translational processing of the protein (e.g., glycosylation).
Mass spectroscopy analysis confirmed the presence of
Leu- and Met-enkephalin in skin extracts (Figure 1d and e).
Specifically, a mass of 556.27 with a retention time of
7.4minutes in skin extract was identical to the m/z at 556.27
and retention time of 7.4minutes of the Leu-enkephalin
standard (the calculated mass of Leu-enkephalin is
556.27711) (Figure 1d). The predicted C13 isotope at m/z
557.23 in skin extract was identical to the standard C13
isotope (Figure 1d, right). The software predicted a chemical
formula of C28H38N5O7. Similarly, an m/z at 574.23 and a
retention time of 6.7minutes was detected in skin extract
(Figure 1e) and dermal fibroblasts extract (not shown). It was
identical to the mass 574.23 and retention time 6.7minutes
of the Met-enkephalin standard (the accurate mass of Met-
enkephalin is 574.223) (Figure 1e). The predicted C13 isotope
at m/z 575.23 was also identical to the standard C13 isotope
(Figure 1e, lower right). On the basis of the above mass, the
software predicted a chemical formula of C27H36N5O7S.
Thus, by matching the predicted chemical formulas and the
extracted chromatograms of the skin and standards, Met- and
Leu-enkephalin were identified in the human skin.
We also performed real-time quantitative reverse-tran-
scription–PCR to quantify PENK mRNA in selected skin
samples and found the highest expression of PENK mRNA in
fibroblasts, lower levels in keratinocytes similar to in those in
Figure 1. Expression of proenkephalin (PENK) in human skin. (a) RT-PCR detection of PENK mRNA. HaCaT keratinocytes (1), melanocytes (2), adult epidermal
keratinocytes (3), dermal fibroblasts (4), and WM98 (5), WM164 (6), and WM1341 (7) melanomas; markers (M). (b) Western blot detection of PENK (left, arrow),
and negative control incubated with nonimmune serum (right). The dividing line in the left panel separates the HaCaT sample from molecular markers, which,
in the right panel, shows the normal skin cells from melanomas. (c) PENK immunoreactivity in HaCaT keratinocytes (left panel), neonatal epidermal melanocytes
(middle panel), and negative control (HaCaT keratinocytes) (right panel). Bar¼50 mm. (d, e) Time-of-flight liquid chromatography mass spectrometry
identification of Leu-enkephalin (d) and Met-enkephalin (e) in skin (sample). Peptide standard (STD). Left: retention times; right: m/z of peptides with C13
isotopes. (f, g) Relative expression of PENK mRNA in comparison with melanoma (¼1) (f) and Leu-enkephalin (g) was measured using Taqman technology and
ELISA, respectively. Data are means±SEM (n¼ 4–8). FIB, dermal fibroblasts; KER, epidermal keratinocytes.
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skin biopsy specimens, and very low levels, comparatively, in
melanoma cells (Figure 1f). Concerning detection of Leu-
enkephalin by ELISA in the culture medium above skin cells,
its levels were negligible in melanoma cells and melanocytes,
whereas high Leu-enkephalin levels were detected in the
medium above keratinocytes and fibroblasts, with an
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approximately twofold difference between the two cell types
(Figure 1g).
PENK protein is expressed in a tissue-specific pattern in human skin
PENK-derived peptide expression (as assessed by immuno-
histochemistry in normal human scalp frozen sections using
antibodies that recognize both Met- and Leu-enkephalins)
was seen predominantly in epidermal and follicular kerati-
nocytes (Figure 2a, b, d–f, h, i), being absent in appropriate
controls incubated with antibodies preabsorbed with en-
kephalin peptides (Figure 2c and g). In the epidermis, PENK
immunoreactivity was markedly restricted to differentiating
keratinocytes of the stratum spinosum and granulosum,
whereas the proliferating basal keratinocytes were negative
(Figure 2a and b). Interestingly, an intense expression of Met/
Leu-enkephalin was detected below the basal membrane
zone and a faint stain was seen in the dermis (asterisk, D),
indicating potential local release of the enkephalin peptides
(Figure 2a and b). In the hair follicle, the cytoplasmic stain
was seen mainly in keratinocytes of the outer root sheath and
basal lamina of the anagen hair follicle (Figure 2f and g).
Antigen expression was also seen in fibroblasts of both the
perifollicular dermal sheath and the follicular papilla (FP)
(Figure 2e and f). Again, a very faint stain was seen in the
extracellular region (Figure 2e and f), indicating potential
local release of the peptides. In addition, immunoreactivity
was also detected in myoepithelial cells of the eccrine glands
(Figure 2h and i).
The above pattern (predominant cytoplasmic stain in
epidermal and follicular keratinocytes) was conserved in
SB
SB
B
D
D
∗
D
ORS
DP
DP
DP
ORS
DP
∗
∗
∗
B
Figure 2. Localization of proenkephalin (PENK)-derived Met- and Leu-enkephalin peptides in normal human scalp skin. (a, b) PENK expression in suprabasal
keratinocytes (SB), base membrane zone (arrow), and dermis (D, asterisk) and its absence in basal keratinocytes (B, asterisk). (c) Negative control for PENK
(peptide block) in the skin, i.e., pre-absorption of primary antibody with 1:1 mix of Leu/Met-enkephalin (see Materials and Methods). (d–f) PENK peptides in the
outer root sheath (ORS) (arrow, d, e) of anagen VI hair follicle (HF), basal lamina (arrow, e), fibroblasts of the dermal sheath (asterisk, d, arrow, f), and follicular
dermal papilla (DP, e). (g) Negative control for PENK (peptide block) in HF. (h, i) PENK peptides in myoepithelial cells (arrows) of the eccrine glands.
(a) Bar¼60 mm; (b) bar¼20 mm; (c) bar¼60 mm; (d) bar¼ 100 mm; (e, f) bar¼ 50 mm; (g) bar¼ 100 mm; (h, i) bar¼ 20 mm.
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formalin-fixed paraffin-embedded samples of diseased skin
(Figure 3; Table 1), but with some differences depending on
the diagnostic features. For example, strong to moderate and
exclusively cytoplasmic stain was seen in keratinocytes of the
stratum spinosum and granulosum (arrow), with very low or
absent immunoreactivity in the stratum basale (arrowheads)
of reviewed cases of seborrheic keratosis, lichenoid keratosis,
melanocytic nevi, and granuloma annulare (Figure 3a–d,
Table 1). Variable intradermal stain was present only in
occasional inflammatory cells. By contrast, both basal and
suprabasal keratinocytes showed increased cytoplasmic
(arrows; double arrowheads for stratum basale) expression
of PENK in psoriatic skin; no epidermal gradient stain was
seen in the normal scalp or in the lesions listed above
(Table 1, Figure 3e). Very low cytoplasmic expression was
detected in nevocytes of melanocytic nevi (asterisks in Figure
3d) and in melanomas (in situ and nodular, asterisks) (Table 1,
Figure 3f and g). Interestingly, epidermal keratinocytes in
melanocytic nevus exhibited strong suprabasal expression,
which was in contrast to melanomas, in which epidermal
keratinocytes of all layers of the epidermis showed weaker
staining. Neither intradermal spindle cells of the dermatofi-
broma nor histiocytic cells of the granuloma annulare
expressed detectable PENK (Table 1). Interestingly, a faint
stain was present in the extracellular matrix of the dermis of
pathological skin in some cases.
PENK expression is regulated in melanocytes and keratinocytes
The observed increased expression of PENK in keratinocytes
of psoriatic skin, together with its inflammatory basis,
suggested that PENK expression may be regulated by
inflammatory stimuli. Thus, we sought to determine whether
PENK expression in keratinocytes can be regulated by TLR
agonists such as lipopolysaccharide (TLR4) and PAM3CSK4
(TLR2). Lipopolysaccharide induced PENK gene expression in
a time- and dose-dependent manner (Figure 4a–c), with a
maximal effect (3.45±0.78-fold) at 1 hour of incubation and
at a concentration of 1 mgml1 (Figure 4a and b). Moreover,
flow-cytometric analysis of keratinocytes stimulated with
lipopolysaccharide also showed significantly increased ex-
pression of intracellular PENK protein (Figure 4c). This
experiment was repeated three times with similar results.
We also tested the effect of the TLR2 agonist PAM3CSK4 on
normal human epidermal keratinocytes and found that, at a
concentration of 1 mgml1, it also stimulated PENK mRNA
expression, with a maximal effect (2.91±0.58-fold) at 1 hour
of incubation (Figure 4d).
Another environmental stressor of the skin, UVB, caused a
time- and dose-dependent stimulation of PENK mRNA
expression in both epidermal keratinocytes and melanocytes
(Figure 5a–d). In melanocytes this effect was maximal
(2.64±1.02-fold) at 6 hours and at a dose of 100mJ cm2
(Figure 5c and d), whereas in epidermal keratinocytes the
effect was maximal (8.18±0.45-fold) after 1 hour and at a
UVB dose of 25mJ cm2 (Figure 5a and b). To obtain
additional proof for the concept that UVB can stimulate PENK
gene transcription, we transfected AtT-20 cells with a PENK-
luc construct and demonstrated that UVB stimulated the
promoter activity in a dose-dependent manner (Figure 5f).
The use of AtT-20 cells was dictated by good transfection
efficiency in these cells, which contrasted with the poor
transfectability of normal epidermal cells.
DISCUSSION
The skin plays a significant part in the protection of both local
and central homeostasis. There is increasing support for a
contribution by the cutaneous neuroendocrine system,
including the opiate system (Slominski and Wortsman,
2000; Slominski et al., 2000c; Bigliardi-Qi et al., 2004;
Feldman et al., 2004; Kauser et al., 2004). In this study,
we demonstrated a differential and cell type–dependent
Figure 3. Localization of proenkephalin (PENK) antigens in pathological
human skin. Immunolocalization of PENK in granuloma annulare
(a), lichenoid keratosis (b), dermatofibroma (c), melanocytic nevus (d),
psoriasis (e), melanoma in situ (f), and nodular malignant melanoma (g).
Negative control represents skin with psoriasis (see e) in which primary
antibodies were omitted (h). Arrows indicate PENK staining in the suprabasal
layer, arrowheads indicate negative PENK staining in the basal layer, double
arrowheads show basal PENK staining; asterisks indicate weak stain in the
intradermal nevocytes and melanoma cells. Skin sections were stained with
anti-PENK antibody, followed by secondary antibody linked to fluorescein.
Insets show high magnification of cells indicated by squares. Bar¼50 mm.
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expression of PENK mRNA, protein, and Leu- and Met-
enkephalin peptides in human skin and in cultured human
normal and malignant skin cells. Using skin biopsies, we
localized in situ Leu- and Met-enkephalin antigens to
epidermal and outer root sheath follicular keratinocytes,
myoepithelial cells of eccrine glands, and some fibroblasts of
the follicular dermal sheath and FP of normal human skin.
This spatial expression pattern and intensity were consider-
ably altered by skin pathology. Furthermore, physical (UVB)
and biological (lipopolysaccharide and TLR2 agonist
PAM3CSK4) stressors demonstrated cell type–specific
time- and dose-dependent stimulation of PENK expression.
So far, the best documentation for local cutaneous
production of endogenous peptide with opioid activity has
been provided for b-endorphin, which results from regulated
expression and processing of the proopiomelanocortin
precursor (Slominski et al., 1992, 2000c; Furkert et al.,
1997; Slominski, 1998; Mazurkiewicz et al., 2000; Kauser
et al., 2004). The present study clearly demonstrates that
human skin and cultured skin cells (normal and pathological)
have the capability to transcribe and translate the PENK gene,
with its subsequent processing to Leu- and Met-enkephalins,
in a cell type–dependent manner, as demonstrated by
RT-PCR, quantitative real-time PCR, western blotting,
immunocytochemistry, time-of-flight/liquid chromatography
mass spectrometry, and ELISA (Figures 1–3). The highest
expression of PENK mRNA was found in cultured dermal
fibroblasts in comparison with epidermal keratinocytes and
normal skin. This would be consistent with predominant
expression of PENK gene in cells of mesenchymal origin
during embryogenesis or its expression in mesenchymal cells
of embryonal skin, both of which have undifferentiated
potential (Polakiewicz and Rosen, 1990; Polakiewicz et al.,
1992). However, the difference in Leu-enkephalin produc-
tion/secretion between cultured fibroblasts and keratinocytes
was much lower—e.g., a difference of only twofold (Figure
1g)—indicating similar or only moderately different potency
to produce and release peptides.
In situ analysis showed much stronger expression of PENK
antigen in epidermal (suprabasal) and follicular keratinocytes
(outer root sheath) in comparison with dermal fibroblasts; the
latter was restricted to cells of the perifollicular dermal sheath
and the FP. This pattern indicates in vivo compartmentaliza-
tion of Met- and Leu-enkephalin antigens, with strong
expression in differentiating epidermal (no expression in
basal) and follicular keratinocytes (outer root sheath) and
selective expression in cells of mesenchymal origin, includ-
ing specialized fibroblasts of the perifollicular dermal sheath
and FP and myoepithelial cells of the eccrine glands. Faint,
extracellular accumulation of Met- and Leu-enkephalin
Table 1. Results of staining with enkephalin antibody
Sample Skin disease PENK immunostaining
1 Granuloma annulare Homogenously stained (+++) epidermal suprabasal keratinocytes; only occasional inflammatory cells
are positive in the dermis
2 Cellular hemorrhagic cellular
dermatofibroma
Heterogeneous (+), (++), or (+++) stain of epidermal keratinocytes; occasional (+) single spindle cells
in the dermis
3 Squamous cell carcinoma Heterogeneous (+) stain of malignant keratinocytes; (++) of hair follicle keratinocytes
4 Lichenoid keratosis Homogenous (++) to (+++) stain in epidermal suprabasal keratinocytes, (+) in follicular keratinocytes
5 Seborrheic keratosis Homogenous (++) stain in suprabasal epidermal and follicular keratinocytes
6 Psoriasis Irregular (+++) stain in basal and (++) stain in spinous layers of keratinocytes; (+) stain in sparse
inflammatory cells in the dermis
7 Psoriasis (++) Stain in basal and spinous layers keratinocytes; (+) stain in sparse inflammatory cells in dermis
8 Intradermal melanocytic nevus () Nevus cells
9 Intradermal melanocytic nevus,
neurotized
Heterogeneous, predominantly () to (+) or occasionally (++) stain in nevus cells
10 Intradermal melanocytic nevus (+) Nevus cells
11 Melanocytic nevus, compound
lentiginous type
Heterogeneous () or (+) stain in nevus cells, (+++) stain in suprabasal keratinocytes
12 Intradermal melanocytic nevus (+) Stain in nevus cells, (++) stain in epidermal keratinocytes
13 Invasive melanoma, VGP Heterogeneous, predominantly () with occasional (/+) stain in melanoma cells, (+) stain in
keratinocytes in stratum spinosum and granulare
14 Melanoma in situ () Stain in melanoma cells, heterogeneous (+) stain in suprabasal epidermal keratinocytes
15 Invasive melanoma, VGP Heterogeneous, () to (+) stain in melanoma cells, (+) in epidermal keratinocytes
16 Nodular malignant melanoma (/+) Stain in melanoma cells, (++) in occasional inflammatory cells
Abbreviation: VGP, vertical growth phase.
In all cases, staining was granular and cytoplasmic.
Immunostain: () negative, (+) weakly positive, (++) positive, (+++) strongly positive.
618 Journal of Investigative Dermatology (2011), Volume 131
AT Slominski et al.
Proenkephalin Expression in Human Skin
antigens in the papillary dermis and perifollicular location
and in FP (see the asterisks in Figure 2b and d) also suggests
secretion of final peptides by fibroblasts to the extracellular
environment.
Epidermal keratinocytes are responsible for building a
dynamic barrier protecting the skin and the body from
environmental insults, including physical and biological
factors (Elias, 2005), whereas melanocytes protect against
solar damage via production of melanin pigment (Slominski
et al., 2004). Therefore, we used both cell types to measure
the effects of UVR on the expression of the PENK gene. The
UVB stimulation of proenkephalin mRNA expression in
melanocytes and keratinocytes in a time- and dose-depen-
dent manner shows that solar radiation can act as an inducer
of PENK gene expression (Figure 5). This has been
substantiated by the demonstration that UVR also stimulates
PENK promoter activity in a dose-dependent manner (Figure
5f). These findings are in agreement with an earlier study
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showing that UVR wavelengths of solar radiation stimulate
Met-enkephalin deposition in the human epidermis as well as
increase the serum concentration of the peptide (Nissen et al.,
1998). In this context, UVR-induced PENK expression may
represent part of the complex local neuropeptide responses to
noxious physical stimuli, which already involve UVR
stimulation of the proopiomelanocortin and corticotropin-
releasing factor signaling systems (Slominski and Wortsman,
2000; Slominski et al., 2000c, 2006). This is particularly
relevant for epidermal keratinocytes, as these cells express
opioid receptors and respond to enkephalins (Zagon et al.,
1996; Nissen and Kragballe, 1997). In the analogous, and
already well-documented, cutaneous proopiomelanocortin
system, the processing of a large precursor protein generates
the neuropeptides a-MSH, adrenocorticotropin, and
b-endorphin, with differential activity aimed at protection
against solar radiation (Slominski et al., 2004, 2008b). Also,
activation of skin nerve endings by b-endorphin may directly
transmit signals to the brain via local nociceptive or opioid
effects induced by solar radiation (Slominski and Wortsman,
2000; Slominski et al., 2000c). In the above context,
enkephalins could represent a part of additional UVB-
induced skin responses that would involve activation of
opioid receptors on the cutaneous sensory nerves, a subject
that deserves future study.
We also have found that lipopolysaccharide and
PAM3CSK4 (TLR4 and TLR2 agonists, respectively) stimulate
PENK gene and protein expression (Figure 4), which is
consistent with stimulation of PENK expression by lipopoly-
saccharide in immune cells and adrenal glands, antimicrobial
functions of PENK-derived peptides (Goumon et al., 1998;
Metz-Boutigue et al., 2000, 2003a, b; Tasiemski et al., 2000a;
Kieffer et al., 2003), and their immunomodulatory functions
(Kamphuis et al., 1997, 1998; Stefano et al., 2005). Therefore,
we propose that activation of PENK in keratinocytes by TLR2
and TLR4 agonists represents a part of the epidermal innate
immune response (Metz-Boutigue et al., 2003b) to protect
against biological stressors and maintain the integrity of local
homeostasis (Slominski et al., 2008b). The role of enkepha-
lins in the innate immune response is highly conserved, being
found even in invertebrates, where lipopolysaccharide also
stimulates enkephalins (Tasiemski et al., 2000b). With respect
to human skin, we observed a striking gradient of Met- and
Leu-enkephalin expression in the epidermis, with the highest
expression being in their outer differentiated keratinocyte
layers and along the basement membrane separating the
nonvascular epidermis from the highly vascularized dermis.
In our opinion, this intriguing architectural pattern may
reflect involvement of PENK-derived peptides in building an
antimicrobial barrier to protect deeper skin layers from
microbial invasion and further colonization of the dermal
compartment, where access to the systemic circulation is
readily available. In addition, this characteristic epidermal
gradient of enkephalin expression, including accumulation in
the stratum corneum, is consistent not only with a role of
PENK-derived peptides in building innate immunity but also
with their direct antibacterial and antifungal activity that has
been conserved in various organisms for more than 500
million years of evolution (Tasiemski et al., 2000b;
Metz-Boutigue et al., 2003b). Additionally, this barrier can
function to alleviate systemic effects such as responses to
pain via the nociceptive actions of enkephalin peptides
(Wilson et al., 1999; Yeomans et al., 2004), as sensory nerve
endings can penetrate into the epidermis and there is
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Figure 5. UVB stimulates expression of proenkephalin (PENK) mRNA in
normal human epidermal keratinocytes and melanocytes. Keratinocytes:
time (at 25mJ cm2) (a) and dose (at 1 hour) (b) responses of PENK mRNA
expression were measured using Taqman technology. Melanocytes: time
(at 100mJ cm2) (c) and dose (at 6 hours) (d) responses of PENK mRNA levels
were measured using Sybr Green technology. Data are means±SEM (n¼ 3).
*Po0.05 versus control. (e) PENK-luc reporter plasmid (lower panel)
containing PENK promoter sequence (772 to þ11 bp) and pLINTER cloning
vector coding promoterless firefly luciferase (upper panel). (f) UVB stimulates
the PENK promoter in AtT-20 cells. After transfection with pPENK-luc, cells
were treated with UVB at 25, 50, 75, and 100mJ cm2. Results represent a
fold change in luciferase activity in comparison with control.
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significant innervation along the basement membrane zone
(Slominski and Wortsman, 2000; Arck et al., 2006).
Concerning skin pathology, it is remarkable that PENK
expression is increased, with a disappearance of the
epidermal gradient, in psoriasis; e.g., it is also expressed in
basal proliferating keratinocytes. This is consistent with a
previous report on increased expression of enkephalin
antigens in this disease (Nissen et al., 1999). This diffuse
pattern also appears to be consistent with the opinion that a
pathologically hyperactive epidermal/immune response to
bacterial superantigens is an important mechanism in the
etiology of psoriasis (Travers et al., 2001). In contrast to a
remarkable expression of PENK in inflammatory skin
disorders (Table 1), it is significantly decreased in melano-
cytic nevi, with further decrease or loss in advanced
melanomas. Interestingly, PENK expression decreases in
keratinocytes of melanoma-involved skin and loses its
characteristic gradient. The significance of these findings
awaits further investigation on a much larger number of skin
biopsies with specific focus on defined pathology. However,
based on this limited number of formalin-fixed, –paraffin-
embedded sections, one can safely conclude that PENK
expression is deregulated in pathological skin in a pattern
dependent on the nature of pathology.
In conclusion, we document that human skin is a site of
proenkephalin expression, showing cell-type and tissue-
compartment specificity. This expression can be regulated
by solar radiation or biological factors (TLR2 and TKR4
agonists) and deregulated by pathology. These findings
indicate paracrine and autocrine modes of action for PENK-
derived peptides, with a potential role in the formation of the
antimicrobial and biological protective barrier and the
regulation of local homeostasis in addition to being a
contributor to locally generated nociceptive or opioid effects.
MATERIALS AND METHODS
Human skin samples
Normal adult skin was obtained after elective surgery and neonatal
skin after circumcision. Pathological skin samples for immunocyto-
chemical and immunofluorescence analyses, obtained from paraffin
blocks containing excision specimens, were retrieved from the
surgical pathology files at the University of Tennessee Health
Science Center (see Supplementary Table S1 online). The diagnoses
were made by a board-certified dermatopathologist. The studies
were approved by the local institutional review board. Other details
are available in the Supplementary material online.
Leu-enkephalin ELISA
Leu-enkephalin levels in supernatants from stimulated melanocytes,
keratinocytes, fibroblasts, and melanoma cells were quantitated
using Leucine-Enkephalin EIA kit EK-024-21 (Phoenix Pharmaceu-
ticals, Belmont, CA) following the manufacturer’s instructions.
Statistical analyses
Data are presented as means±SEM (n¼ 3–4) and were analyzed
using the Student t-test (for two groups) or one-way analysis of
variance with appropriate post-hoc tests (for more than two groups)
using Prism 4.00 (GraphPad Software, San Diego, CA). Statistically
significant differences between control and treated groups are
denoted by asterisks: *Po0.05, **Po0.01, ***Po0.005.
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